Overactive Bladder - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Overactive Bladder – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Overactive Bladder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Overactive Bladder: Overview
Overactive bladder (OAB) is the name for a group of urinary symptoms. It is not a disease. The most common symptom is a sudden, uncontrolled need or urge to urinate. Some people will leak urine when they feel this urge. Another symptom is the need to pass urine many times during the day and night. It is a chronic medical condition which has a tremendous impact on the quality of life in both men and women. OAB affects performance of daily activities and social function such as work, traveling, physical exercise, sleep, and sexual function. A basic understanding of how the urinary system operates is needed to understand the cause of Overactive Bladder. The kidneys produce the urine and send it to the bladder. The bladder expands to holds the urine while the sphincter muscle acts as a spiget and controls the flow of urine. An understanding of the pathophysiology of OAB may facilitate effective treatment. Normal urinary function involves complex interactions between the cortex of the brain, the pons, the spinal cord (with the peripheral autonomic, somatic, and sensory afferent and efferent innervation of the lower urinary tract), and the anatomic components of the urinary tract itself. There are six antimuscarinic agents available for the treatment of OAB worldwide: oxybutynin, tolterodine, fesoterodine, trospium, darifenacin, and solifenacin. All the six antimuscarinic agents have shown similar efficacy, however their extended release versions have shown lower side effects compared to immediate release versions due to a decreased fluctuation in serum concentration.
'Overactive Bladder - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Overactive Bladder pipeline landscape is provided which includes the disease overview and Overactive Bladder treatment guidelines. The assessment part of the report embraces, in depth Overactive Bladder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Overactive Bladder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Overactive Bladder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Overactive Bladder Emerging Drugs
Further product details are provided in the report……..
Overactive Bladder: Therapeutic Assessment
This segment of the report provides insights about the different Overactive Bladder drugs segregated based on following parameters that define the scope of the report, such as:
Overactive Bladder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Overactive Bladder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Overactive Bladder drugs.
Overactive Bladder Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Overactive Bladder – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Overactive Bladder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Overactive Bladder: Overview
Overactive bladder (OAB) is the name for a group of urinary symptoms. It is not a disease. The most common symptom is a sudden, uncontrolled need or urge to urinate. Some people will leak urine when they feel this urge. Another symptom is the need to pass urine many times during the day and night. It is a chronic medical condition which has a tremendous impact on the quality of life in both men and women. OAB affects performance of daily activities and social function such as work, traveling, physical exercise, sleep, and sexual function. A basic understanding of how the urinary system operates is needed to understand the cause of Overactive Bladder. The kidneys produce the urine and send it to the bladder. The bladder expands to holds the urine while the sphincter muscle acts as a spiget and controls the flow of urine. An understanding of the pathophysiology of OAB may facilitate effective treatment. Normal urinary function involves complex interactions between the cortex of the brain, the pons, the spinal cord (with the peripheral autonomic, somatic, and sensory afferent and efferent innervation of the lower urinary tract), and the anatomic components of the urinary tract itself. There are six antimuscarinic agents available for the treatment of OAB worldwide: oxybutynin, tolterodine, fesoterodine, trospium, darifenacin, and solifenacin. All the six antimuscarinic agents have shown similar efficacy, however their extended release versions have shown lower side effects compared to immediate release versions due to a decreased fluctuation in serum concentration.
'Overactive Bladder - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Overactive Bladder pipeline landscape is provided which includes the disease overview and Overactive Bladder treatment guidelines. The assessment part of the report embraces, in depth Overactive Bladder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Overactive Bladder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Overactive Bladder R&D. The therapies under development are focused on novel approaches to treat/improve Overactive Bladder.
This segment of the Overactive Bladder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Overactive Bladder Emerging Drugs
- Neuronox: AbbVie/Medytox
- URO-902: Sumitovant Biopharma
Further product details are provided in the report……..
Overactive Bladder: Therapeutic Assessment
This segment of the report provides insights about the different Overactive Bladder drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Overactive Bladder
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Overactive Bladder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Overactive Bladder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Overactive Bladder drugs.
Overactive Bladder Report Insights
- Overactive Bladder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Overactive Bladder drugs?
- How many Overactive Bladder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Overactive Bladder?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Overactive Bladder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Overactive Bladder and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Overactive Bladder: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Neuronox: AbbVie/Medytox
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
URO-902: Sumitovant Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
HG-102: Hugel
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Overactive Bladder Key Companies
Overactive Bladder Key Products
Overactive Bladder- Unmet Needs
Overactive Bladder- Market Drivers and Barriers
Overactive Bladder- Future Perspectives and Conclusion
Overactive Bladder Analyst Views
Overactive Bladder Key Companies
Appendix
Executive Summary
Overactive Bladder: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Neuronox: AbbVie/Medytox
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
URO-902: Sumitovant Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
HG-102: Hugel
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Overactive Bladder Key Companies
Overactive Bladder Key Products
Overactive Bladder- Unmet Needs
Overactive Bladder- Market Drivers and Barriers
Overactive Bladder- Future Perspectives and Conclusion
Overactive Bladder Analyst Views
Overactive Bladder Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Overactive Bladder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Overactive Bladder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Overactive Bladder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Overactive Bladder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
